47E7CB22-BC33-4D50-AF1B-5134C350B9D4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.22996057818659657
- age_years
- 71
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.565
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.545
- IL6_JAK_STAT3_SIGNALING+0.505
- ALLOGRAFT_REJECTION+0.504
- INTERFERON_GAMMA_RESPONSE+0.480
- INTERFERON_ALPHA_RESPONSE+0.466
- COAGULATION+0.432
- MYC_TARGETS_V2+0.409
- NOTCH_SIGNALING+0.395
- TNFA_SIGNALING_VIA_NFKB+0.394
Top 10 suppressed
- SPERMATOGENESIS-0.354
- PANCREAS_BETA_CELLS-0.268
- HEDGEHOG_SIGNALING-0.142
- KRAS_SIGNALING_DN-0.129
- PROTEIN_SECRETION-0.098
- MYC_TARGETS_V1-0.058
- CHOLESTEROL_HOMEOSTASIS-0.039
- MITOTIC_SPINDLE+0.019
- HEME_METABOLISM+0.028
- MYOGENESIS+0.039
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.919 |
| 2 | 25B5E54F-5858-454C-9B23-440A82450912 | — | — | 0.896 |
| 3 | BS_M85CXHDV | high-grade glioma | — | 0.893 |
| 4 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.888 |
| 5 | SRR934845 | — | — | 0.887 |
| 6 | 6727027F-4BAB-41ED-87F3-ECC7B1718ECF | — | — | 0.883 |
| 7 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.883 |
| 8 | SRR934897 | — | — | 0.881 |
| 9 | 59B8FDC4-299D-45B9-9AC1-526B7ED652CE | — | — | 0.880 |
| 10 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.565 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.545 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.505 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.504 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.466 | Inavolisib | — uncovered |
| COAGULATION | 0.432 | Binimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.409 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.395 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.394 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.391 | Idelalisib | — uncovered |
| COMPLEMENT | 0.382 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| APOPTOSIS | 0.356 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.286 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.284 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.284 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.258 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.248 | Idelalisib | — uncovered |